<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id><journal-id journal-id-type="publisher-id">abd</journal-id><journal-title-group><journal-title>Anais Brasileiros de Dermatologia</journal-title></journal-title-group><issn pub-type="ppub">0365-0596</issn><issn pub-type="epub">1806-4841</issn><publisher><publisher-name>Sociedade Brasileira de Dermatologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28954098</article-id><article-id pub-id-type="pmc">5595596</article-id><article-id pub-id-type="doi">10.1590/abd1806-4841.20175496</article-id><article-categories><subj-group subj-group-type="heading"><subject>Investigation</subject></subj-group></article-categories><title-group><article-title>Pilot study of homologous platelet gel in venous ulcers<xref ref-type="fn" rid="fn1">*</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Oliveira</surname><given-names>Mariele Gobo</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abbade</surname><given-names>Luciana Patricia Fernandes</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Miot</surname><given-names>H&#x000e9;lio Amante</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Rosana Rossi</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Deffune</surname><given-names>Elenice</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Nursing, Botucatu Medical School - S&#x000e3;o Paulo
State University "J&#x000fa;lio de Mesquita Filho" (UNESP) - Botucatu (SP),
Brazil.</aff><aff id="aff2">
<label>2</label> Department of Dermatology and Radiotherapy, Botucatu Medical School
- S&#x000e3;o Paulo State University "J&#x000fa;lio de Mesquita Filho" (UNESP) -
Botucatu (SP), Brazil.</aff><aff id="aff3">
<label>3</label> Department of Biological Sciences, Faculty of Sciences of Bauru -
S&#x000e3;o Paulo State University "J&#x000fa;lio de Mesquita Filho" (UNESP) -
Botucatu (SP), Brazil.</aff><aff id="aff4">
<label>4</label> Cellular Engineering Laboratory, Botucatu Medical School -
S&#x000e3;o Paulo State University "J&#x000fa;lio de Mesquita Filho" (UNESP) -
Botucatu (SP), Brazil.</aff><author-notes><corresp id="c1">Mailing address: Luciana Patricia Fernandes Abbade, Departamento de
Dermatologia, s/n, Faculdade de Medicina de Botucatu da UNESP, Campus
Universit&#x000e1;rio de Rubi&#x000e3;o Jr., 18618-970 - Botucatu, SP, Brazil.
Email: <email>lfabbade@fmb.unesp.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2017</year></pub-date><volume>92</volume><issue>4</issue><fpage>499</fpage><lpage>504</lpage><history><date date-type="received"><day>10</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial No Derivative License, which
permits unrestricted non-commercial use, distribution, and reproduction in
any medium provided the original work is properly cited and the work is not
changed in any way.</license-p></license></permissions><abstract><sec><title>Background</title><p>Venous ulcers represent 70% of the lower limb ulcers. They are difficult to
heal, requiring a correct diagnostic and therapeutic approach. Many products
have been developed to healing, such as homologous platelet gel obtained
from the platelet concentrate exceeding from blood transfusion.</p></sec><sec><title>Objective</title><p>To evaluate the safety and efficacy of homologous platelet gel in venous
ulcers compared with hydrocolloid dressing.</p></sec><sec><title>Method</title><p>A pilot randomized clinical trial in patients with venous ulcers. Randomized
groups (homologous platelet gel and hydrocolloid groups) were followed for
90 days and were assessed through the evolution of ulcerated area,
qualitative analysis of vascularization and adverse events. Both groups used
elastic compression.</p></sec><sec><title>Results</title><p>We included 16 participants, with a total of 21 venous ulcers. Both
treatments promoted a reduction of the areas of the ulcers in 90 days (mean
69%), there was significant difference between the groups concerning the
gradual reduction of the ulcers areas, favorably to the hydrocolloid (70% vs
64%; p &#x0003c;0.01). There were some mild adverse events in both groups.</p></sec><sec><title>Study limitations</title><p>Single-center study with a small number of patients, preventing more accurate
assessment of the effects of platelet gel.</p></sec><sec><title>Conclusion</title><p>The homologous platelet gel associated with the elastic compression can be an
alternative to the venous ulcer treatment and is safe due to the occurrence
of a few mild local adverse events and no serious adverse events. Clinical
trials with larger numbers of patients must be performed to maintain the
indication of this treatment for venous ulcer.</p></sec></abstract><kwd-group><kwd>Wound healing, hydrocolloid bandages</kwd><kwd>Platelet-Rich plasma</kwd><kwd>Varicose ulcer</kwd></kwd-group><funding-group><award-group><funding-source>FAPESP</funding-source><award-id>2009/03559-3</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Venous ulcers (VUs) represent 70% of lower limb ulcers, with a prevalence of 0.06 to
2% in the population.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> They
constitute a serious public health problem, which contributes to burden public
spending in the Brazilian public healthcare system, as well as interfering in the
quality of life of the population due to complications that may result in
significant morbidity.<sup><xref rid="r2" ref-type="bibr">2</xref></sup> Despite the
high prevalence and its importance, it is often neglected and approached
inappropriately.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Studies
aiming at rapid healing strategies are important.</p><p>Due to the difficult healing, VUs need a correct diagnostic and therapeutic approach.
In this sense, many products have been developed for healing, such as the homologous
platelet gel (PG), obtained from the concentrated blood platelet, exceeding from
blood transfusion.<sup><xref rid="r4" ref-type="bibr">4</xref></sup> This strategy
aims to obtain an effective dressing by means of the release of growth factors in
the wound bed, with the advantage of having low cost.</p><p>This study aimed to evaluate the safety and efficacy of homologous PG in VU comparing
it with the hydrocolloid dressing.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a pilot study of a randomized and prospective clinical trial design, with
participants with VUs, conducted at the Department of Dermatology of the Clinics
Hospital of Botucatu Medical School - Unesp between March/2010 and January/2011. It
was approved by the Research Ethics Committee of the Botucatu Medical School - Unesp
(n&#x000ba; 538/08). All participants accepted and signed the Informed Consent Form.</p><p>The inclusion criteria were: participants aged &#x0003e;18 years with VU, presence of good
granulation tissue, defined as having a bright red color. Exclusion criteria were:
presence of associated peripheral arterial disease, characterized when the
ankle-brachial index was lower than 0.9, history of osteomyelitis and presence of
critical colonization/ infection in the wound bed.</p><p>Randomization was generated using Microsoft Excel and, subsequently, matched
envelopes were made, identified numerically and opened in sequential order at the
time of inclusion of the patient. VUs were randomized and divided into groups using
platelet gel (PG) and hydrocolloid dressing (HC). Patients from both groups received
guidance for daily use of compressive elastic band
(Surepress<sup>&#x000ae;</sup>).</p><p>Participants were followed up for 90 days, with monthly assessments (D<sub>0</sub>,
D<sub>30</sub>, D<sub>60</sub>, D<sub>90</sub>), conduction of clinical
consultations and measurement of evolution of the ulcer area through standardized
digital photography.<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p><p>Photographs were made with Sony Cyber-shot digital camera<sup>TM</sup> 7.2
megapixels, at a fixed distance of approximately 15 cm from the injured area.
Lesions were identified with a label (1.2 x 2.6 cm), which served as reference point
in centimeters for the edge border design and area calculation. Measurement was
performed using the freely available Image J software, available at: <ext-link ext-link-type="uri" xlink:href="http://rsbweb.nih.gov/ij/">http://rsbweb.nih.gov/ij/</ext-link> (<xref ref-type="fig" rid="f1">Figure
1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Sequence of application of platelet gel</p></caption><graphic xlink:href="abd-92-04-0499-g01"/></fig>
</p><p>Vascularization was evaluated by anatomopathological examination at D<sub>0</sub> and
D<sub>90</sub> for completely or exulcerated unhealed ulcers, with a 4 mm
dermatological punch at the margin of the lesion. For histological analysis,
hematoxylin-eosin (HE) staining and immunohistochemistry (IHC) were conducted.
Anti-CD34 monoclonal antibody diluted 1: 150 (QBEnd 10) was used as the primary
antibody for IHC reactions. Sections were washed in PBS, incubated for 30 minutes
with biotinylated secondary antibody, followed by 30 minutes of incubation with
streptavidin peroxidase complex (LSAB, DAKO, Carpinteria, CA, USA). Labeling was
performed by incubating the slides with 3.3'-diaminobenzidine (DAB) and stained with
hematoxylin. For CD34 immunostaining analysis, a comparison of the variation of the
IHC scores by the chi-square test of the trend from the bootstrap simulation was
performed from 10,000 simulations.</p><p>Dressing of both groups included cleaning with saline 0.9%, heated in jet application
of the covering according to randomization, secondary dressing and elastic
compression band (Surepress<sup>&#x000ae;</sup>). The secondary dressing was changed
daily at home and the primary dressing of both groups was changed every four days at
home or at a Basic Health Unit. For use of the hydrocolloid dressing, 10 x 10 cm
plates of the brands Coloplast<sup>&#x000ae;</sup>, Curatec<sup>&#x000ae;</sup> and
Casex<sup>&#x000ae;</sup> were used, according to availability on the
Service.</p><p>PG was produced from a pool of the concentrated blood platelet group, validated as an
intravenous blood product, in compliance with all legal requirements of the National
Health Surveillance Agency (ANVISA). The blood components were surplus of the
transfusion practice, being obtained by voluntary blood donation from the
Hemotherapy service, and, therefore, presenting serological and microbiological
control.</p><p>PG has a laminar shape, that is, it has the appearance of a membrane and a gelatinous
consistency, which is formed when thrombin and calcium gluconate are added to the
platelet rich plasma (PRP) under sterile conditions supplemented with the
antioxidants agents (<xref ref-type="fig" rid="f2">Figure 2</xref>). It was handled
in a Laminar Flow Cabinet and then stored at 4&#x000b0;C in Petri dishes.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Morphology of vessels (<bold>A, B and C</bold> - general characteristic
of lesions in D0). <bold>A:</bold> vascular proliferation, ++ / ++++
intensity in the papillary dermis, arrangement tending to non-cohesive
(Hematoxylin &#x00026; eosin X200); <bold>B:</bold> Marking by CD34,
evidencing vessel in the papillary dermis (IHC X200); C: Vessels in
detail with irregular lights, tending to be disposed at 90&#x000ba; in the
epidermis, with few endothelial cells (Hematoxylin &#x00026; eosin X400);
<bold>D, E, F:</bold> vessel morphology of lesions of the group
treated with HC in D90 (Hematoxylin &#x00026; eosin X200, IHC X200 and
Hematoxylin &#x00026; eosin X400); <bold>G, H and I:</bold> vessel
morphology of lesions of the group treated with PG in D90 (Hematoxylin
&#x00026; eosin X200, IHC X200 and Hematoxylin &#x00026; eosin X400)</p></caption><graphic xlink:href="abd-92-04-0499-g02"/></fig>
</p><p>The evaluated endpoints were: safety of the use of the products through possible
local adverse events, such as pain (through the Numerical Visual Scale), contact
dermatitis, critical colonization/ infection and increased ulceration. Percentage of
reduction of the ulcerated area (calculated from the initial area subtracted from
the final area and divided by the initial area), angiogenesis and characteristics of
each dressing (patient compliance, dressing changing time, ease of manipulation in
both application and removal of the dressing, appearance of lesion and exudate
edges, and wrapping).</p><p>Categorical variables were represented by their percentage proportions and compared
between the groups by Fisher's exact test or trend chi-square with exact
probability.</p><p>Continuous variables were represented by their means and standard deviations or
medians and quartiles (p25-p75), if normality was not identified by the Shapiro-Wilk
test. Groups were compared by Student's t-test or Mann-Whitney, if indicated.</p><p>Longitudinal variables were evaluated according to the intention to treat population.
Groups were compared through a generalized linear model of mixed effects, with
unstructured covariance structure, gamma probability distribution (identity) and
robust analysis. Experimental unit of analysis used was the ulcerated area in
cm<sup>2</sup>.</p><p>Data were analyzed in IBM SPSS 22.0 software. Statistical significance was determined
at 5%.</p></sec><sec sec-type="results"><title>RESULTS</title><p>Sixteen participants were included, with a total of 21 VUs: 9 ulcers were randomized
to the PG group and 12 to the HC group. Demographic and clinical characteristics of
patients and characteristics of lesions are presented in <xref ref-type="table" rid="t1">table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of PG and HC participants and lesion
characteristics</p></caption><table frame="void" rules="groups" style="background-color:#eee8ef"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">PG (n=9)*</th><th align="center" rowspan="1" colspan="1">HC (n=12)*</th><th align="center" rowspan="1" colspan="1">p-value</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Sex - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Women</td><td align="center" rowspan="1" colspan="1">5 (56)</td><td align="center" rowspan="1" colspan="1">8 (67)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">10 (63)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Men</td><td align="center" rowspan="1" colspan="1">4 (44)</td><td align="center" rowspan="1" colspan="1">4 (33)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">6 (37)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age (year) - mean (dp)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">55 (18)</td><td align="center" rowspan="1" colspan="1">70 (8)</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">62.3 (15.6)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Color - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">White</td><td align="center" rowspan="1" colspan="1">6 (67)</td><td align="center" rowspan="1" colspan="1">9 (75)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">11 (69)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Brown</td><td align="center" rowspan="1" colspan="1">2 (22)</td><td align="center" rowspan="1" colspan="1">2 (17)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3 (19)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Black</td><td align="center" rowspan="1" colspan="1">1 (11)</td><td align="center" rowspan="1" colspan="1">1 (8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">2 (12)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BMI - N (%)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">18-25</td><td align="center" rowspan="1" colspan="1">3 (33)</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">5 (31)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">25-30</td><td align="center" rowspan="1" colspan="1">2 (22)</td><td align="center" rowspan="1" colspan="1">7 (58)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">7 (44)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">30-40</td><td align="center" rowspan="1" colspan="1">4 (45)</td><td align="center" rowspan="1" colspan="1">2 (17)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">SAH - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">5 (56)</td><td align="center" rowspan="1" colspan="1">6 (50)</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">8 (50)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">DM - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4 (44)</td><td align="center" rowspan="1" colspan="1">2 (17)</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">5 (31)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Recurrence - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">5 (56)</td><td align="center" rowspan="1" colspan="1">11 (92)</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">16 (76)<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Ulcer time (months)- median (p25-p75)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">24 (8-72)</td><td align="center" rowspan="1" colspan="1">21 (8-114)</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">24 (8-108)<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pain* - N (%)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Mild (1-3)</td><td align="center" rowspan="1" colspan="1">6 (67)</td><td align="center" rowspan="1" colspan="1">4 (33)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">10 (48)<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Moderate (4-6)</td><td align="center" rowspan="1" colspan="1">3 (33)</td><td align="center" rowspan="1" colspan="1">7 (59)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">10 (48)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Severe (7-9)</td><td align="center" rowspan="1" colspan="1">0 (-)</td><td align="center" rowspan="1" colspan="1">1 (8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Location - N (%)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Medial</td><td align="center" rowspan="1" colspan="1">2 (22)</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">5 (24)<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Lateral</td><td align="center" rowspan="1" colspan="1">6 (67)</td><td align="center" rowspan="1" colspan="1">7 (58)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">13 (62)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Anterior/Posterior</td><td align="center" rowspan="1" colspan="1">0 (-)</td><td align="center" rowspan="1" colspan="1">1 (8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Back of the foot</td><td align="center" rowspan="1" colspan="1">1 (11)</td><td align="center" rowspan="1" colspan="1">1 (8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">2 (10)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Margin Feature - N (%)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Fine</td><td align="center" rowspan="1" colspan="1">5 (56)</td><td align="center" rowspan="1" colspan="1">3 (25)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">8 (38)<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Thick</td><td align="center" rowspan="1" colspan="1">4 (44)</td><td align="center" rowspan="1" colspan="1">9 (75)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">13 (62)</td></tr><tr><td align="left" rowspan="1" colspan="1">LM Edema - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">7 (78)</td><td align="center" rowspan="1" colspan="1">6 (50)</td><td align="center" rowspan="1" colspan="1">0.37</td><td align="center" rowspan="1" colspan="1">10 (63)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Lipodermatosclerosis - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4 (44)</td><td align="center" rowspan="1" colspan="1">9 (75)</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">9 (56)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LM varicoses - N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3 (33)</td><td align="center" rowspan="1" colspan="1">9 (75)</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">8 (50)<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Data on 21 VUs;</p></fn><fn id="TFN2"><label>**</label><p>Data regarding the 16 patients; PG - Platelet gel; HC - Hydrocolloid;
BMI: Body Mass Index; SAH: Systemic Arterial Hypertension; DM: Diabetes
Mellitus.</p></fn></table-wrap-foot></table-wrap><p>In the studied population, women (63%) predominated, with a mean age of 62.3 years,
with systemic arterial hypertension being the most frequent comorbidity (50%). The
history of ulcer recurrence was 76%.</p><p>Lesions had a median of 24 months of active ulcer time, predominantly on the lateral
side (62%) and thicker margins (62%). Lower limb edema was the most frequent
perilesional characteristic (63%). The groups did not differ in the initial size of
the ulcers (p = 0.13), nor their duration (p = 0.81).</p><p>It should be noted the homogeneity in clinical and demographic parameters (except
age), the reduction of areas in both groups, the absence of effects due to
treatments and the low percentage of adverse events at follow-up (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Evolution of ulcer areas and local adverse events during follow-up of PG and
HC participants</p></caption><table frame="void" rules="groups" style="background-color:#eee8ef"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">PG (n=9)*</th><th align="center" rowspan="1" colspan="1">HC (n=12)*</th><th align="center" rowspan="1" colspan="1">p-value</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">Ulcer area
(cm<sup>2</sup>)-median(p25-p75)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;D0</td><td align="center" rowspan="1" colspan="1">7.4(5.5-10.3)</td><td align="center" rowspan="1" colspan="1">16.1(6.2-47.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">10.3(5.8-18.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;D90</td><td align="center" rowspan="1" colspan="1">2.7(1.5-3.7)</td><td align="center" rowspan="1" colspan="1">4.9(2.3-21.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3.2(1.5-21.3)</td></tr><tr><td colspan="5" align="left" rowspan="1">Adverseevent-N(%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Criticalcolonization</td><td align="center" rowspan="1" colspan="1">4(44)</td><td align="center" rowspan="1" colspan="1">2(17)</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">6(29)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Increased area</td><td align="center" rowspan="1" colspan="1">3(33)</td><td align="center" rowspan="1" colspan="1">1(8)</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">4(19)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p><bold>PG -</bold> Platelet gel; <bold>HC -</bold> Hydrocolloid.</p></fn></table-wrap-foot></table-wrap><p>There were no ulcers at the time evaluated that presented complete healing.</p><p>Individual measurements of VU area at each visit are shown in graph 1. Both
treatments promoted a significant reduction (p&#x0003c;0.01) in the areas of the ulcers
in 90 days (mean 69%) and there was a significant difference between the groups
regarding progressive reduction of ulcer areas favoring HC (70% vs. 64%,
p&#x0003c;0.01).</p><p>When adjusted for age, varicose veins and recurrence of ulcers, variables in which
the groups were different at p&#x0003c;0.20, the statistical difference between the
groups (p &#x0003c;0.01) was maintained, favoring treatment with HC.</p><p>Regarding neovascularization, biopsies of 9 participants were analyzed, totaling 10
VUs, 7 of the HC group and 3 of the PG group, who remained in the study until
D<sub>90</sub> (<xref ref-type="fig" rid="f2">Figure 2</xref>). There was no
difference between the groups in the evaluation of the scores between D<sub>0</sub>
and D<sub>90</sub> (p = 0.67).</p><p>Observed characteristics of both dressings were described in <xref ref-type="table" rid="t3">chart 1</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Chart 1</label><caption><p>Clinical characteristics observed in HC and PG groups</p></caption><table frame="void" rules="groups" style="background-color:#dcd1de"><colgroup span="1"><col width="30%" span="1"/><col width="3%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Observation criteria</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">HC</th><th align="center" rowspan="1" colspan="1">PG</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patient compliance</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Easier to be known in different UBS and easy to
self-apply.</td><td align="center" rowspan="1" colspan="1">Predicted resistance for new products and difficulty
of self-application.</td></tr><tr><td align="left" rowspan="1" colspan="1">Changing time</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4 days</td><td align="center" rowspan="1" colspan="1">4 days</td></tr><tr><td align="left" rowspan="1" colspan="1">Ease of handling (application and removal)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Higher. The removal is easy, however it requires a
discreet traction.</td><td align="center" rowspan="1" colspan="1">Lower. More fragile and slippery in application,
however the removal done is only of the gauze, because the dressing
is totally absorbed.</td></tr><tr><td align="left" rowspan="1" colspan="1">Appearance of ulcer</td><td align="center" rowspan="1" colspan="1">Margins</td><td align="center" rowspan="1" colspan="1">Causes maceration</td><td align="center" rowspan="1" colspan="1">In good conditions</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Exudate</td><td align="center" rowspan="1" colspan="1">With sui generis odor, unpleasant, referred by the
patient.</td><td align="center" rowspan="1" colspan="1">The exudate of the primary dressing gets a
reddish-brown appearance, with a discreet odor not mentioned by the
patient.</td></tr><tr><td align="left" rowspan="1" colspan="1">Storage</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Room temperature</td><td align="center" rowspan="1" colspan="1">Refrigerator 4&#x000ba;C</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>HC-Hydrocolloid; PG - Platelet gel</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This pilot study, although with a small number of patients, was randomized, with a
control group and obeying the methodology of clinical trials to evaluate the
efficacy and safety of VU treatment.</p><p>PG showed to be an alternative in the treatment of VUs. Although the area reduction
percentage of the PG group was lower than that of the HC group, PG also presented a
good percentage of area reduction, approximately 64%, which has been reported in
other studies in the treatment of VUs. A study by Scotton <italic>et
al.</italic><sup><xref rid="r6" ref-type="bibr">6</xref></sup> with 137 VUs
verified an area reduction of 50% or more using different dressings associated with
the use of elastic compression.</p><p>HC group presented an area reduction of 70%. In a systematic review of 42 studies of
VU treatment, no statistically significant difference was found in relation to ulcer
healing regardless of the dressing used, and the use of the hydrocolloid associated
with elastic compression was not beneficial when compared with simple dressing with
low adherence.<sup><xref rid="r7" ref-type="bibr">7</xref></sup></p><p>On the use of homologous PG, there are few studies on venous ulcers. Bernuzzi
<italic>et al.</italic>
<sup><xref rid="r8" ref-type="bibr">8</xref></sup>, using autologous and homologous
PG in ulcers of different etiologies, verified area reduction of &#x0003e;50% in the
period of 96 days. Frykberg <italic>et al.</italic>
<sup><xref rid="r9" ref-type="bibr">9</xref></sup>, using autologous platelet-rich
plasma in ulcers of different etiologies, found improvement in 97% of the lesions,
with a mean area reduction of 39.5%. In another similar study, with the use of
autologous platelet-rich plasma, the area reduction found was 47.5% in 86.3% of
lesions. <sup><xref rid="r10" ref-type="bibr">10</xref></sup></p><p>The healing effects of PG can be attributed to the release of innumerable growth
factors after platelet activation, which suggests that the therapy is similar to
natural healing by the application of multiple growth factors in a biological
way.<sup><xref rid="r11" ref-type="bibr">11</xref></sup> A variety of growth
factors have been reported as participant in the tissue repair process, including
EGF, PDGF, FGF, TGF-&#x003b2;1 and IGF-1. <sup><xref rid="r12" ref-type="bibr">12</xref></sup></p><p>Choosing to use the homologous PG is due to its low cost, since it uses surplus
platelet of blood transfusion, and also due to the comfort to the patient. Shan
<italic>et al.</italic>
<sup><xref rid="r11" ref-type="bibr">11</xref></sup> reported that the preparation
and storage of autologous PG limit its clinical use, because in addition to being
uncomfortable to the patient, for each application it is necessary a new blood
collection, which stimulates the homologous PG proposal.</p><p>Demographic and clinical characteristics were homogeneous between the groups, except
for age, and agreed with those reported in previous studies, such as women
predominance, age around 60 years and hypertension as the more frequent comorbidity.
<sup><xref rid="r13" ref-type="bibr">13</xref></sup></p><p>Lesion and perilesional characteristics, as well as the history of ulcer recurrence,
are those commonly found in patients with VUs. In general, VUs have an irregular
shape, with well-defined borders, which can become deep with yellowish exudate, and
present eczema, ocher dermatitis and perilesional lipodermosclerosis.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Prevalence of recurrence was 76%; a
study conducted by Finlayson <italic>et al.</italic>
<sup><xref rid="r14" ref-type="bibr">14</xref></sup> found 78% of VU recurrence in
patients followed up for three years, having as risk factors history of deep vein
thrombosis, multiple anterior leg ulcers and a longer duration of anterior
ulcer.</p><p>It was observed that PG presented adverse events, such as critical colonization and
increased area, but without statistical difference in relation to HC group. This is
probably due to the fact that PG contains a large amount of proteins and tissue
growth factors that also become excellent means of culturing bacteria and, in its
preparation, there is no incorporation of antibacterial agents. Other
characteristics observed in relation to the use of dressings were the difficulties
of handling PG, which evidences the need for improvements of the product to
facilitate its use, as well as the addition of antimicrobial agents to its formula
to avoid bacterial proliferation and, thus, improve the healing rates that can be
obtained with this product.</p><p>Our study has limitations: it is unicentric, with a small number of patients, which
made impossible a more precise evaluation of PG.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Homologous platelet gel associated with compressive treatment showed favorable
results for its indication in the treatment of venous ulcers, being safe due to the
occurrence of few mild local adverse events and the absence of serious adverse
events. Clinical trials with a larger number of patients and allowing the
exploration of subgroups should substantiate the proper indication of this
treatment.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Conflict of interest: None.</p></fn><fn fn-type="other" id="fn1"><label>*</label><p>Study conducted at Clinics Hospital of Botucatu Medical School - S&#x000e3;o Paulo
State University "J&#x000fa;lio de Mesquita Filho" (UNESP) - Botucatu (SP),
Brazil.</p></fn><fn fn-type="supported-by"><p>Financial support: FAPESP financial grant (n&#x000ba; 2009/03559-3).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>TF Jr</given-names></name><name><surname>Passman</surname><given-names>MA</given-names></name><name><surname>Marston</surname><given-names>WA</given-names></name><name><surname>Ennis</surname><given-names>WJ</given-names></name><name><surname>Dalsing</surname><given-names>M</given-names></name><name><surname>Kistner</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Management of venous leg ulcers : Clinical practice guidelines of
the Society for Vascular Surgery and the American Venous
Forum</article-title><source>J Vasc Surg</source><year>2014</year><volume>60</volume><fpage>3S</fpage><lpage>59S</lpage><pub-id pub-id-type="pmid">24974070</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>TYAF</given-names></name><name><surname>Costa</surname><given-names>IKF</given-names></name><name><surname>Melo</surname><given-names>MDM</given-names></name><name><surname>Torres</surname><given-names>SMSGSO</given-names></name><name><surname>Maia</surname><given-names>EMC</given-names></name><name><surname>Torres</surname><given-names>GV</given-names></name></person-group><article-title>Avalia&#x000e7;&#x000e3;o da qualidade de vida de pacientes com e
sem &#x000fa;lcera venosa</article-title><source>Rev Latino-Am Enferm</source><year>2014</year><volume>22</volume><fpage>576</fpage><lpage>581</lpage></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbade</surname><given-names>LPF</given-names></name><name><surname>Last&#x000f3;ria</surname><given-names>S</given-names></name></person-group><article-title>Abordagem de pacientes com &#x000fa;lcera da perna de etiologia
venosa</article-title><source>An Bras Dermatol</source><year>2006</year><volume>81</volume><fpage>509</fpage><lpage>522</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroz</surname><given-names>A</given-names></name><name><surname>Deffune</surname><given-names>E</given-names></name></person-group><article-title>Platelet-rich plasma and chronic wounds: remaining fibronectin
may influence matrix remodeling and regeneration success</article-title><source>Cytotherapy</source><year>2013</year><volume>15</volume><fpage>1436</fpage><lpage>1439</lpage><pub-id pub-id-type="pmid">23993645</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miot</surname><given-names>HA</given-names></name><name><surname>Menda&#x000e7;olli</surname><given-names>TJ</given-names></name><name><surname>Costa</surname><given-names>SV</given-names></name><name><surname>Haddad</surname><given-names>GR</given-names></name><name><surname>Abbade</surname><given-names>LPF</given-names></name></person-group><article-title>&#x000da;lceras cr&#x000f4;nicas dos membros inferiores:
avalia&#x000e7;&#x000e3;o pela fotografia digital</article-title><source>Rev Assoc Med Bras</source><year>2009</year><volume>55</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">19488648</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scotton</surname><given-names>MF</given-names></name><name><surname>Miot</surname><given-names>HA</given-names></name><name><surname>Abbade</surname><given-names>LP</given-names></name></person-group><article-title>Factors that influence healing of chronic venous leg ulcers : a
retrospective cohort</article-title><source>An Bras Dermatol</source><year>2014</year><volume>89</volume><fpage>414</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">24937814</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palfreyman</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>EA</given-names></name><name><surname>Michaels</surname><given-names>JA</given-names></name></person-group><article-title>Dressings for venous leg ulcers : systematic review and
meta-analysis</article-title><source>BMJ</source><year>2007</year><volume>335</volume><fpage>244</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">17631512</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernuzzi</surname><given-names>G</given-names></name><name><surname>Tardito</surname><given-names>S</given-names></name><name><surname>Bussolati</surname><given-names>O</given-names></name><name><surname>Adorni</surname><given-names>D</given-names></name><name><surname>Cantarelli</surname><given-names>S</given-names></name><name><surname>Fagnoni</surname><given-names>F</given-names></name><etal/></person-group><article-title>Platelet gel in the treatment of cutaneous ulcers: the experience
of the Immunohaematology and Transfusion Centre of Parma</article-title><source>Blood Transfus</source><year>2010</year><volume>8</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">20967164</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frykberg</surname><given-names>RG</given-names></name><name><surname>Driver</surname><given-names>VR</given-names></name><name><surname>Carman</surname><given-names>D</given-names></name><name><surname>Lucero</surname><given-names>B</given-names></name><name><surname>Borris-Hale</surname><given-names>C</given-names></name><name><surname>Fylling</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Chronic wounds treated with a physiologically relevant
concentration of platelet-rich plasma gel: a prospective case
series</article-title><source>Ostomy Wound Manage</source><year>2010</year><volume>56</volume><fpage>36</fpage><lpage>44</lpage></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>JM</given-names></name><name><surname>Driver</surname><given-names>VR</given-names></name><name><surname>Fylling</surname><given-names>CP</given-names></name><name><surname>Carter</surname><given-names>MJ</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><etal/></person-group><article-title>The clinical relevance of treating chronic wounds with an
enhanced near-physiological concentration of platelet-rich plasma
gel</article-title><source>Adv Skin Wound Care</source><year>2011</year><volume>24</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">21768787</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>GQ</given-names></name><name><surname>Zhang</surname><given-names>YN</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Zuo</surname><given-names>DM</given-names></name><name><surname>Qiu</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Evaluation of the effects of homologous platelet gel on healing
lower extremity wounds in patients with diabetes</article-title><source>Int J Low Extrem Wounds</source><year>2013</year><volume>12</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">23509083</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boateng</surname><given-names>JS</given-names></name><name><surname>Matthews</surname><given-names>KH</given-names></name><name><surname>Stevens</surname><given-names>HN</given-names></name><name><surname>Eccleston</surname><given-names>GM</given-names></name></person-group><article-title>Wound healing dressings and drug delivery systems: a
review</article-title><source>J Pharm Sci</source><year>2008</year><volume>97</volume><fpage>2892</fpage><lpage>2923</lpage><pub-id pub-id-type="pmid">17963217</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Almeida Medeiros</surname><given-names>AB</given-names></name><name><surname>de Queiroz Fraz&#x000e3;o</surname><given-names>CM</given-names></name><name><surname>de S&#x000e1; Tin&#x000f4;co</surname><given-names>JD</given-names></name><name><surname>Nunes de Paiva</surname><given-names>Md</given-names></name><name><surname>de Oliveira Lopes</surname><given-names>MV</given-names></name><name><surname>Brand&#x000e3;o de Carvalho Lira</surname><given-names>AL</given-names></name></person-group><article-title>Venous ulcer: risk factors and the Nursing Outcomes
Classification</article-title><source>Invest Educ Enferm</source><year>2014</year><volume>32</volume><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">25230036</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlayson</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>ML</given-names></name><name><surname>Edwards</surname><given-names>HE</given-names></name></person-group><article-title>Identifying risk factors and protective factors for venous leg
ulcer recurrence using a theoretical approach: A longitudinal
study</article-title><source>Int J Nurs Stud</source><year>2015</year><volume>52</volume><fpage>1042</fpage><lpage>1051</lpage><pub-id pub-id-type="pmid">25801312</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f3" orientation="portrait" position="float"><label>Graph 3</label><caption><p>Ulcer is (Log<sub>2</sub>), at each visit, for each group</p><p>p (model) &#x0003c;0.01; Akaike Information criteria = 691.80;</p><p>p (time) &#x0003c;0.01; p (group) = 0.60; p (time*group) &#x0003c;0.01.</p></caption><graphic xlink:href="abd-92-04-0499-g03"/></fig></floats-group></article>